OAM
KNSA icon

Oxford Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Oxford Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-39,991
Closed -$442K – 780
2019
Q4 		$442K Buy
+39,991
New +$347K 0.01% 1287

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oxford Asset Management's KNSA Position: Q1 2020 in Review

Oxford Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2020, closing a stake of 39,991 shares — an estimated $442K sold.

Oxford Asset Management first reported a position in KNSA in Q4 2019 and held it in 1 quarter. The position peaked at $442K in Q4 2019. 77 funds tracked by Wall St. Rank hold KNSA as of Q1 2020.

  • Oxford Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 39,991 Kiniksa Pharmaceuticals shares in Q1 2020, an estimated $442K.
  • Oxford Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Kiniksa Pharmaceuticals position peaked at $442K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.